GIMOTI™ (metoclopramide), novel nasal spray developed by Evoke Pharma, Inc specifically for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Diabetic gastroparesis refers to GI disorder affecting millions of patients worldwide.With the current treatments available in the market patients claim that there is no sufficient relief for their gastroparesis symptoms. This unique non-oral treatment optionhelps patients to relieve symptoms and help improve their quality of life.
Most common symptoms of patients suffering from gastroparesis are nausea, abdominal pain, bloating, early satiety as well as vomiting which can be severe and debilitating.GIMOTI is administered nasally, bypassing the diseased GI track, allowing the drug to enter the bloodstream directly and therefore providing predictable delivery of the therapy.
US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI™ (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
